What drives intraday moves in NOVN.SW stock?

Intraday moves for NOVN.SW stock are driven by clinical readouts, corporate announcements, and volume spikes. Recent Phase III data for remibrutinib and Vanrafia, plus the Indian stake sale, explain heightened trading.

What is Meyka AI’s grade for NOVN.SW stock?

Meyka AI gives NOVN.SW a **77.68** score, Grade **B+** with a **BUY** suggestion. The grade weighs benchmarks, sector, growth, metrics, forecasts, and analyst signals.

What near-term price should traders watch for NOVN.SW stock?

Near-term technical levels: intraday support at **CHF126.16** and resistance near the year high **CHF129.54**. Meyka AI’s quarterly forecast is **CHF127.28**.

How do valuation metrics look for NOVN.SW stock?

Valuation is mixed: **PE 23.27**, **Price/Book 6.86**, and **Free Cash Flow yield 5.31%**. Strong ROE and cash flow offset a premium price-to-book multiple.

CH Stocks

NOVN.SW Novartis (SIX) at CHF126.48 intraday 24 Feb 2026: watch pipeline catalysts

ByDanny Kontos February 24, 2026February 24, 2026

We note NOVN.SW stock trading at CHF126.48 intraday on 24 Feb 2026, driven by heavy activity on the SIX exchange. Volume stands at 2,517,608 shares, making Novartis one of the most active names in Swiss healthcare today. Price has oscillated between CHF126.16 and CHF128.08 so far. We focus on clinical catalysts, earnings timing, and valuation metrics that connect recent news to the stock move. As an AI-powered market analysis platform, Meyka AI tracks these inputs in real time for traders and investors.